Soluble ST2 levels in patients with cardiogenic and septic shock are not predictors of mortality

Experimental and Clinical Cardiology

Volumn 17, Issue 4, 2012, Pages 205-209

  Parenica, Jiri ^a,b,c   Malaska, Jan ^a,b   Jarkovsky, Jiri ^b   Lipkova, Jolana ^b   Dastych, Milan ^a,b   Helanova, Katerina ^a,b   Litzman, Jiri ^b,c   Tomandl, Josef ^b   Littnerova, Simona ^b   Sevcikova, Jana ^b   Gal, Roman ^a,b   Sevcik, Pavel ^a,b   Spinar, Jindrich ^a,b,c   Goldbergova, Monika Pavkova ^b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Cardiogenic shock; Circulating levels; Septic shock; ST2

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE; INTERLEUKIN RECEPTOR; PROCALCITONIN; SOLUBLE ST2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOGENIC SHOCK; CARDIOVASCULAR MORTALITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; FEMALE; HORMONE BLOOD LEVEL; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SEPTIC SHOCK; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

EID: 84872815199     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Dinarello CA. An IL-1 Family member requires caspase-1 processing and signals through the ST2 receptor. Immunity 2005;23:461-2.
2. Kakkar R, Lee RT. The IL-33/ST2 pathway: Therapeutic target and novel biomarker. Nat Rev Drug Discov 2008;7:827-40.
3. Weinberg EO, Shimpo M, De Keulenaer GW et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002;106:2961-6.
4. Weinberg EO, Shimpo M, Hurwitz S, Tominaga Si, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003;107:721-6.
5. Januzzi Jr JL, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: Results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) Study. J Am Coll Cardiol 2007;50:607-13.
6. Dhillon OS, Narayan HK, Quinn PA, Squire IB, Davies JE, Ng LL. Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: Comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP. Am Heart J 2011;161:1163-70.
7. Eggers KM, Armstrong PW, Califf RM, et al. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am Heart J 2010;159:788-94.
8. Sabatine MS, Morrow DA, Higgins LJ, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008;117:1936-44.
9. Shimpo M, Morrow DA, Weinberg EO, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004;109:2186-90.
10. Hoogerwerf J, Tanck M, van Zoelen M, Wittebole X, Laterre PF, van der Poll T. Soluble ST2 plasma concentrations predict mortality in severe sepsis. Intensive Care Med 2010;36:630-7.
11. Kohsaka S, Menon V, Low AM, et al. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic schock. Arch Intern Med 2005;165:1643-1.
12. Reynolds HR, Hochman JS. Cardiogenic shock: Current concepts and improving outcomes. Circulation 2008;117:686-97.
13. Bouhemad B, Nicolas-Robin A, Arbelot C, Arthaud M, Féger F, Rouby JJ. Acute left ventricular dilatation and shock-induced myocardial dysfunction. Crit Care Med 2009;37:441-7.
14. Task FM, Van de Werf F, Bax J, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J 2008;29:2909-45.
15. Alexander JH, Reynolds HR, Stebbins AL, et al. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock. JAMA 2007;297:1657-66.
16. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-6.
17. Manzano-Fernández S, Mueller T, Pascual-Figal D, Truong Q, Januzzi J. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 2011;107:259-67.
18. Oshikawa K, Kuroiwa K, Tago K, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001;164:277-81.
19. Kuroiwa K, Arai T, Okazaki H, Minota S, Tominaga S. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun 2001;284:1104-8.
20. Hong YS, Moon SJ, Joo YB, et al. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci 2011;26:1132-9.
21. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007;117:1538-49.
22. Seki K, Sanada S, Kudinova AY, et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009;2:684-91.
23. Pirracchio R, Deye N, Lukaszewicz AC, et al. Impaired plasma B-type natriuretic peptide clearance in human septic shock. Crit Care Med 2008;36:2542-6.
24. Weir RA, Miller AM, Murphy GE, et al. Serum soluble ST2: A potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol 2010;55:243-250.
25. Kumar S, Tzimas MN, Griswold DE, Young PR. Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli. Biochem Biophys Res Commun 1997;235:474-8.
26. de Pablo Rl, Monserrat J, Reyes E, et al. Mortality in patients with septic shock correlates with anti-inflammatory but not proinflammatory immunomodulatory molecules. J Intensive Care Med 2011;26:125-32.
27. Debrunner M, Schuiki E, Minder E. Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock. Clin Res Cardiol 2008;97:298-305.
28. Brunkhorst FM, Clark AL, Forycki ZF, Anker SD. Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: The potential importance of bacterial translocation. Int J Cardiol 1999;72:3-10.
29. Pudil R, Krejsek J, Pidrman V, Gregor J, Tichy M, Bures J. Inflammatory response to acute myocardial infarction complicated by cardiogenic shock. Acta Medica (Hradec Kralove) 2001;44:149-151.